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Abstract
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these antibodies develop remain
important goals in the quest to rationally develop an HIV-1 vaccine. We previously identified a participant in the CAPRISA
Acute Infection Cohort (CAP257) whose plasma neutralized 84% of heterologous viruses. In this study we showed that
breadth in CAP257 was largely due to the sequential, transient appearance of three distinct broadly neutralizing antibody
specificities spanning the first 4.5 years of infection. The first specificity targeted an epitope in the V2 region of gp120 that
was also recognized by strain-specific antibodies 7 weeks earlier. Specificity for the autologous virus was determined largely
by a rare N167 antigenic variant of V2, with viral escape to the more common D167 immunotype coinciding with the
development of the first wave of broadly neutralizing antibodies. Escape from these broadly neutralizing V2 antibodies
through deletion of the glycan at N160 was associated with exposure of an epitope in the CD4 binding site that became the
target for a second wave of broadly neutralizing antibodies. Neutralization by these CD4 binding site antibodies was almost
entirely dependent on the glycan at position N276. Early viral escape mutations in the CD4 binding site drove an increase in
wave two neutralization breadth, as this second wave of heterologous neutralization matured to recognize multiple
immunotypes within this site. The third wave targeted a quaternary epitope that did not overlap any of the four known sites
of vulnerability on the HIV-1 envelope and remains undefined. Altogether this study showed that the human immune
system is capable of generating multiple broadly neutralizing antibodies in response to a constantly evolving viral
population that exposes new targets as a consequence of escape from earlier neutralizing antibodies.
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Introduction
Neutralizing antibodies are the principal correlate of protection
for most preventative vaccines. Designing suitable vaccine
immunogens to elicit these types of antibodies has been relatively
simple for conserved pathogens such as smallpox and other DNA
viruses. For more diverse pathogens like HIV-1, the neutralizing
antibodies elicited by vaccination or during natural infection are
largely strain-specific and therefore would not be protective
against globally circulating viral variants [1–5]. The HIV-1
envelope glycoprotein spikes mediate viral entry and are the sole
targets for neutralizing antibodies. The spikes are trimeric, made
up of three non-covalently associated gp41-gp120 heterodimers,
each with a conserved core that mediates infection of CD4+ T-
cells. Functionally conserved sites are protected by extensive
glycosylation, and large solvent exposed hypervariable structures
(the V1–V5 loops, and the a2-helix in C3) [6]. All HIV-1 infected
individuals develop strain-specific neutralizing antibodies which
target these sequence variable regions, but only a quarter develop
broadly neutralizing antibodies [7–11], which will likely be needed
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for a preventative HIV-1 vaccine. To engineer an envelope
immunogen that can specifically elicit these antibodies, the HIV-1
vaccine research field has adopted a strategy based largely on
rational design: identifying the targets for these broadly cross-
reactive antibodies, and elucidating the pathways that promoted
their development.
Plasma mapping strategies and the isolation of monoclonal
antibodies have defined four major targets for broadly neutralizing
antibodies on the HIV-1 glycoprotein [7–10,12–20]. The CD4
binding site (CD4bs) of gp120 and the membrane proximal
external region (MPER) of gp41 are glycan independent epitopes,
while the V1/V2 sub-domain and the co-receptor/V3 site on
gp120 are sites of vulnerability for glycan binding antibodies
(predominantly at positions N156/N160 and N301/N332 respec-
tively) [14–16]. Both CD4bs antibodies and co-receptor/V3
antibodies bind well to monomeric gp120, while MPER antibodies
bind to a linear peptide in gp41. This makes it possible to adsorb
out their neutralization activity from plasma with various
recombinant proteins. In contrast the epitope for V2 antibodies
(such as PG9/16) consists of two anti-parallel b-sheets (B- and C-
strands) of a Greek key motif, and the glycans therein, that is
preferentially formed on the native trimer. This region is critically
important for the gp120-gp120 interactions that stabilize the
envelope glycoprotein spike in its unliganded conformation, and
therefore cannot be readily adsorbed [16,21]. Various sub-
epitopes within each of these four major sites of vulnerability
have also been identified through subtle differences in the
mechanism of neutralization [22]. For instance antibodies
targeting the CD4bs can be sub-divided into two groups: those
that are sensitive to the D368A and/or E370A mutations in the
CD4 binding loop a3 (such as VRC01); and those that are
dependent on amino acids D474, M475, and/or R476 in a5
termed CD4bs/DMR (such as HJ16) [23–26]. Despite this
detailed knowledge, epitope mapping strategies have failed to
identify the neutralization targets in a subset of plasma samples [7–
9,17,19,27,28]. The antibodies mediating breadth in these samples
could target sub-epitopes within one of the four sites of
vulnerability or they may target entirely novel epitopes.
In the CAPRISA 002 Acute Infection Cohort, we previously
identified seven individuals with broadly neutralizing antibodies.
In five cases we were able to map the plasma antibody specificities
to known epitopes (two targeted N332, two the V2 epitope, and
one the MPER) [7]. In this study we have focused on one of the
individuals (CAP257) for which the target was undefined.
Heterologous and autologous neutralization data as well as viral
sequences from longitudinal samples were used to identify the
epitopes for CAP257 broadly neutralizing antibodies. We showed
that heterologous neutralization in CAP257 was conferred by
three distinct, sequentially occurring antibody waves, two of which
were mapped to epitopes in V2 and the CD4bs respectively. While
individuals with more than one broadly neutralizing antibody
specificity have been previously identified [29–31], there is little
information on how the dynamic relationship between host and
pathogen contributed to the development of antibodies targeting
multiple epitopes. We have shown previously that escape from
strain-specific neutralizing antibodies can drive the formation of
epitopes for broadly neutralizing antibodies [32]. Here we found
that viral escape from broadly neutralizing antibodies targeting V2
promoted the development of a second broadly neutralizing
antibody response targeting a glycan dependent epitope in the
CD4bs. We also identified early escape mutations from both the
V2 and CD4bs antibodies that drove an increase in the
neutralization breadth of CAP257 plasma. These findings have
implications for the design of HIV-1 vaccine antigens and
sequential immunization strategies.
Results
The broadly neutralizing activity of CAP257 develops in
three distinct waves
We have previously described the development of neutralization
breadth in CAP257 using longitudinal plasma samples from HIV-
1 seroconversion to three years post-infection (p.i.) [7]. Here, we
extended this analysis until the start of anti-retroviral therapy at
four and a half years p.i. (Figure 1A). Longitudinal plasma was
tested against the autologous CAP257 virus amplified from the
earliest available time point (7 weeks p.i.), the subtype C consensus
sequence (ConC) [33], 4 Tier 1b viruses, and 39 Tier 2 viruses
[34]. Autologous neutralizing antibodies appeared by 14 weeks of
infection with a peak titer at two years of 1:6,754. This was
followed by the neutralization of heterologous viruses 30 weeks
after infection. CAP257 neutralized 84% of the heterologous
viruses at three years (174 weeks) with neutralization breadth of
100% against subtype A (6/6 viruses), 96% against subtype C (25/
26 viruses, including ConC), and 50% against subtype B (6/12
viruses). The titers of these broadly neutralizing antibodies peaked
and waned in three separate waves.
The first wave of neutralization breadth (typified by CAP63)
peaked at 67 weeks p.i. with a maximum titer of 1:1,493 and
exclusively neutralized subtype C viruses (Figures 1A and 1B – red
curves). Wave 1 titers dropped to as low as 1:145 by 149 weeks of
infection. As this early heterologous neutralization began to wane,
CAP257 plasma gained the capacity to neutralize additional
subtype C viruses as well as several subtype A and B viruses
(Figures 1A and 1B – blue and green curves). This second wave
(typified by Q842) peaked at 122 weeks p.i. with titers as high as
1:8,565 against RHPA that dropped to 1:1,254 by 213 weeks of
infection. Finally, a third wave of heterologous neutralization
(represented by Du156) appeared by 149 weeks p.i. and peaked at
213 weeks p.i. (Figure 1B – brown curve). This third wave was also
largely subtype C specific. These data suggested that the
Author Summary
Four sites of vulnerability for broadly neutralizing anti-
bodies to HIV-1 have been identified thus far. How these
broadly reactive antibodies arise, and the host-pathogen
interactions that drive the affinity maturation necessary for
neutralization breadth are poorly understood. This study
details the sequential development of three distinct
broadly neutralizing antibody responses within a single
HIV-1 infected individual over 4.5 years of infection. We
show how escape from the first wave of antibodies
targeting V2 exposed a second site that was the stimulus
for a new wave of glycan dependent broadly neutralizing
antibodies against the CD4 binding site. These data
highlight how antibody evolution in response to viral
escape mutations served to broaden the host immune
response to these two epitopes. Finally, we document a
third wave of neutralization that targets an undefined
epitope that did not appear to overlap with the four
known sites of vulnerability on the HIV-1 envelope. These
data support the design of templates for sequential
immunization strategies aimed at increasing neutralization
breadth through the recognition of multiple epitopes and
their immunotypes.
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neutralization breadth of CAP257 plasma was mediated by at least
three distinct antibody specificities.
To identify the targets of each of the three broadly
neutralizing antibody specificities in CAP257 plasma we first
assessed whether they targeted epitopes in monomeric gp120
(such as the CD4bs or N301/N332 glycans). We adsorbed out
the gp120 binding antibodies in plasma samples from the peak
neutralizing activity of each wave using recombinant ConC
gp120 coupled to tosyl-activated magnetic beads (Figure 1C).
The adsorbed plasma was compared with untreated plasma for
activity against a heterologous virus neutralized by each wave.
Neutralization by wave 1 (67 weeks p.i.) and wave 3 (213 weeks
p.i.) was not affected by adsorption with monomeric gp120
(Figure 1C – red and brown curves), however neutralization by
wave 2 antibodies (122 weeks p.i.) could be partially adsorbed
with the ConC gp120 protein (Figure 1C – blue curve). The
neutralizing activity of wave 2 could also be equally adsorbed
with a core gp120 lacking the hypervariable loops V1/V2 and
V3 (Figure 1C – green curve). These data supported our
hypothesis that CAP257 heterologous neutralization was medi-
ated by more than one neutralizing antibody specificity, two of
which were largely subtype C specific and targeted an epitope
not present on monomeric gp120, and a third whose epitope in
gp120 was more conserved across clades and did not require the
hypervariable loops V1/V2 or V3.
Wave 1 broadly neutralizing antibodies target V2
The inability of gp120 to adsorb out wave 1 neutralization
suggested these antibodies might recognize the trimer specific
epitope in V1/V2 defined by PG9/16 [16]. Therefore, we
performed mapping studies using ConC, which was neutralized by
all three waves of neutralizing antibodies (Figure 2A – red curve).
Seven mutations in the V2 region (F159A, N160A, R166A,
K168A, K169E, K171A, and I181A) each abrogated wave 1
neutralization, but did not significantly affect the titers of waves 2
or 3 (Figure 2A – purple curves). In contrast, a D167N mutation
resulted in enhanced neutralization by wave 1 antibodies, but did
not significantly affect the titers of waves 2 or 3 (Figure 2A –
orange curve). A second mutation (L165A) also resulted in
significant neutralization enhancement at all the time points
tested, including those preceding breadth (Figure 2A – grey curve),
suggesting that this mutation resulted in general neutralization
sensitivity. Overall, these data indicated that wave 1 antibodies
(but not waves 2 or 3) targeted residues in the V2 region.
To define whether the V2 epitope recognized by CAP257
plasma antibodies overlapped with that of known broadly
neutralizing antibodies to this site, we tested the sensitivity of
PG9/16, CH01-04, and PGT145 to the same ConC V2 mutations
described above and compared them to CAP257 neutralizing
antibodies at the peak of wave 1 activity, 67 weeks p.i. (Figure 2B).
Of the seven mutations that abrogated CAP257 neutralization
Figure 1. CAP257 broadly neutralizing antibodies develop sequentially in three distinct waves. A) Longitudinal neutralization of the
autologous CAP257 virus (black) and 37 heterologous viruses neutralized by CAP257 plasma at titers .1:100. The ID50 titers (y-axis) are shown versus
weeks p.i. (x-axis). Three peaks in heterologous neutralization titers at 67, 122, and 213 weeks p.i. are indicated with dotted lines. Heterologous
viruses are colored according to subtype (A = green, B = blue, C = red). B) A summary of the three waves of heterologous neutralization defined by a
representative virus, superimposed over the neutralization kinetics shown in Figure 1A. Wave 1 was subtype C specific and is colored red. Wave 2
neutralized viruses from all three clades and is colored green. Wave 3 is colored brown. C) Adsorption of heterologous neutralization at the peak of
each of the three waves. Percentage inhibition (y-axis) is shown versus plasma dilution (x-axis). Untreated plasma is shown in black, blank beads in
grey and beads coated with recombinant proteins are shown in red (wave 1), blue/green (wave 2) or brown (wave 3).
doi:10.1371/journal.ppat.1003738.g001
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only two (N160A and K169E) resulted in complete resistance to all
the antibodies tested, consistent with previous data [35,36].
Neither the monoclonal antibodies nor CAP257 wave 1 antibodies
were sensitive to deletion of the N156 glycan (through the S158A
mutation) in ConC. Lastly, mutations at two hydrophobic amino
acids in V2 (F159A and I181A) that do not form part of the PG9
epitope as defined by the crystal structure [37], had a significant
effect on the neutralization of monoclonal antibodies targeting V2,
and CAP257 wave 1 antibodies.
Immunotype switching within V2 precedes the
development of wave 1 antibodies
To define escape from wave 1 neutralizing antibodies, we
examined sequences from the V2 region of CAP257 over time.
Using single genome amplification (SGA) we obtained 125 full
envelope sequences from twelve time points between 7 and 213
weeks p.i., and focused on the N160 glycan and the cationic C-
strand in V2 that are the targets of wave 1 antibodies (Figure 3A).
Interestingly, the earliest virus (7 weeks p.i.) had an asparagine at
position 167. This N167 residue is rare, occurring in only 5.6%
(196 of 3,478) of sequences in the Los Alamos National Laboratory
(LANL) HIV sequence database. By the time of the earliest
detectable heterologous neutralization (30 weeks p.i., maximum
titer of 1:49) mutations in sites forming part of the wave 1 V2
epitope were already apparent in 6/14 autologous sequences at
positions R166, K169, and Q170 (Figure 3A). Of the remaining
eight sequences, six exhibited other mutations either in the N160
glycosylation sequon or the V1/V2 C-strand. This rapid selection
pressure in the C-strand of V1/V2 was sometimes an N167D
mutation (4/14 autologous sequences) that was unlikely to be
selected for by wave 1 broadly neutralizing antibodies, as all the
heterologous viruses neutralized by wave 1 had a D167 residue.
Since the V1/V2 region is a common target of strain-specific
neutralizing responses [38–41], these data suggested the possibility
of an earlier neutralizing response targeting N167 in V2 that
preceded the development of broadly neutralizing antibodies.
Wave 1 mapping data (Figure 2A) further supported this possibility
because the reverse D167N mutation enhanced the neutralization
of ConC by wave 1 antibodies only, and resulted in earlier
neutralization kinetics (Figure 2A – orange curve).
To test this we selected an envelope from 174 weeks p.i.
(CAP257 3 yr) that was completely resistant to CAP257 neutral-
izing antibodies (consistent with ongoing neutralization escape),
and back-mutated the V1/V2 region to match the earliest
sequence from 7 weeks p.i. (Figure 3B). The neutralization
sensitivity of the back-mutated virus, CAP257 3 yr(V1/V2s), was
then compared to the parental CAP257 3 yr virus using
longitudinal plasma samples. In contrast with the resistant
CAP257 3 yr virus, the back-mutated V1/V2 virus (CAP257
3 yr(V1/V2s)) became sensitive to neutralization at 23 weeks p.i.
(Figure 3B – black curve). This suggested the emergence of a
strain-specific V1/V2 response 7 weeks prior to the development
of wave 1 broadly neutralizing antibodies at 30 weeks p.i.
To establish whether these strain-specific V1/V2 neutralizing
antibodies targeted the same epitope as wave 1 broadly neutralizing
antibodies, we introduced selected escape mutations (N167D, N160D/
S and K169E) into the sensitive CAP257 3 yr(V1/V2s) back-mutated
envelope. Introduction of the N167D mutation (Figure 3B – orange
curve), a common V2 change at 30 weeks p.i., shifted the timing of
autologous V1/V2 neutralization to overlap with the emergence of
wave 1 broad neutralization. The introduction of N160D/S mutations
that deleted the N160 glycan (Figure 3B – purple curves), further
shifted autologous neutralization to overlap with the emergence of
wave 2 neutralizing antibodies. Finally, when the K169E mutation was
introduced (Figure 3B – pink curve), autologous V1/V2 neutralization
titers were completely abrogated. As the N160A and K169E mutations
in ConC also completely abrogated neutralization by CAP257 wave 1
broadly neutralizing antibodies (Figure 2B) these data suggest that the
strain-specific V2 neutralizing antibodies in CAP257 plasma targeted
the same site of vulnerability that was later targeted by wave 1 broadly
Figure 2. The first wave of broadly neutralizing antibodies targets residues in the V2 region. A) Longitudinal neutralization of ConC V2
mutants. ConC wild-type (wt) is shown in red. V2 mutants F159A, N160A, R166A, K168A, K169E, K171A, and I181A that abrogated wave 1
neutralization are shown in purple. The D167N mutation that enhanced wave 1 neutralization is shown in orange, while the L165A mutation that
resulted in universal neutralization sensitivity is shown in grey. The timing of wave 1 (red), wave 2 (green), and wave 3 (brown) neutralization is
summarized above as horizontal lines, while the peak titers at each wave are indicated with dotted lines. ID50 titers (y-axis) are shown versus weeks
p.i. (x-axis). B) The dependence of CAP257 wave 1 neutralizing antibodies (at 67 weeks p.i.) on V2 residues in ConC, compared to monoclonal
antibodies PGT145, CH01-04, and PG9/16. Complete abrogation of neutralization is colored red, 2–10 fold reductions in IC50 are colored yellow, and
.10 fold reductions in IC50 are colored orange.
doi:10.1371/journal.ppat.1003738.g002
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neutralizing antibodies. However the strain-specific V2 antibodies
recognized the rare N167 immunotype of V2 present in the CAP257
infecting virus. Following an early N167D escape mutation at this site,
V1/V2 neutralization became N167 independent, allowing recogni-
tion of the more common D167 immunotype. This switch in the fine
specificity of CAP257 V2 antibodies correlated with the emergence of
broadly neutralizing wave 1 antibodies.
Escape from wave 1 antibodies exposed the epitope for
wave 2 neutralization
Wave 1 broadly neutralizing antibodies were completely
dependent on the glycan at N160 (Figure 2A). Viral escape from
wave 1 neutralizing antibodies by deletion of this glycan first
occurred at 54 weeks p.i. (in 37.5% of the sequences), immediately
prior to the development of wave 2 neutralizing antibodies
(Figure 3A – pie charts). This escape pathway persisted at 93 weeks
p.i. (in 30% of sequences), but by 122 weeks p.i., at the peak of
wave 2 activity, alternative escape pathways existed, and all
sequences contained the N160 glycan. The transient nature of this
highly effective escape pathway suggested that deletion of the
N160 glycan had a deleterious effect on the virus.
A potential mechanism for this came from the observation that
deleting the N160 glycan (critical to wave 1 neutralization) in the
CAP257 3 yr(V1V2s) virus conferred slight neutralization sensi-
tivity coinciding temporally with wave 2 (Figure 3B – purple
curves). These data suggested that mutations at N160 exposed the
Figure 3. Escape from V2 neutralizing antibodies drives the formation/exposure of broadly neutralizing antibody epitopes in the
CD4bs. A) Amino acid sequence alignment of the CAP257 B- and C- strands in the V1/V2 sub-domain of gp120, from twelve time points. The
number of envelopes per unique V2 sequence is shown on the right. The timing of wave 1 (red), wave 2 (green), and wave 3 (brown) neutralization is
summarized to the left with vertical lines. Potential N-linked glycans are shaded grey, and the presence (grey slices) or absence (red slices) of the N160
glycan within the population at each time point is shown with pie charts to the right. B) CAP257 develops a strain-specific V2 response prior to wave
1 broadly neutralizing antibodies. Neutralization of an autologous virus amplified from 174 weeks p.i. (CAP257 3 yr), is shown in grey. The V1/V2
region of this virus was back-mutated to the earliest known sequence (CAP257 3 yr(V1/V2s)) shown in black. Longitudinal neutralization of the
N167D, N160D/S, and K169E mutants is shown in orange, purple, and pink respectively. The timing of wave 1 (red), wave 2 (green), and preceding
strain-specific V2 (black) neutralization is summarized above with horizontal lines. ID50 titers (y-axis) are shown versus weeks p.i. (x-axis). C) Wave 2
neutralization of Q842 (green) or RHPA (blue) wild-type (wt) viruses, and their N160K mutants (purple). The timing of wave 1 (red), wave 2 (green),
and wave 3 (brown) neutralization is summarized above as in Figure 1B. ID50 titers (y-axis) are shown versus weeks p.i. (x-axis).
doi:10.1371/journal.ppat.1003738.g003
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wave 2 epitope. To examine whether loss of the N160 glycan
enhanced CAP257 wave 2 neutralization we selected two viruses,
Q842 and RHPA, which were neutralized at high titer by wave 2
but resistant to wave 1, and deleted the N160 glycan in each. The
effect of these N160K mutations was assessed longitudinally using
CAP257 plasma. While the timing of RHPA N160K and Q842
N160K neutralization by CAP257 was not altered compared to
the wild-type viruses, these mutant viruses were neutralized 2–8
fold more potently by wave 2 antibodies (Figure 3C – purple
curves). A similar 2 fold increase in titer was shown at the peak of
wave 2 activity when the N160 glycan was deleted in ConC
(Figure 2A – purple closed circles). As deletion of the N160 glycan
in the autologous virus occurred prior to the development of wave
2 neutralizing antibodies, these data suggest that this particular
escape pathway from wave 1 neutralizing antibodies may have
contributed to the development of wave 2 antibodies, possibly by
better exposing the epitope. Therefore, after the development of
wave 2, the K169E mutation that also allowed escape from wave 1
broadly neutralizing antibodies, but did not enhance wave 2
neutralization, was preferentially selected over deletion of the
N160 glycan (Figure 3A).
Wave 2 neutralizing antibodies target the CD4bs
The V1/V2 sub-domain of gp120 plays an important role in
shielding the envelope from neutralization. More specifically,
several modifications in V1/V2 (particularly at N-glycosylation
sites) have been implicated in either shielding or exposing the
CD4bs to neutralizing antibodies [42–51]. As escape from wave 1
at N160 enhanced neutralization by wave 2, these data suggested
the CD4bs as the target for wave 2 antibodies. This was supported
by the adsorption data (Figure 1C), showing that wave 2
neutralizing antibodies bound the core gp120 protein. Therefore
we examined envelope sequences from 191 weeks p.i. for selection
pressure in the conserved CD4bs (Figure 4). Three mutations in
the D-loop (N276D/S, T278A/K and N279D) and one at the
base of V5 in the b23 sheet of C4 (R456W) dominated the viral
population at this time point. Both the D-loop and V5 have been
previously implicated in resistance to CD4bs antibodies [52–54].
To assess whether these CD4bs mutations mediated resistance to
wave 2 neutralization, we introduced the three most common
mutations (T278A, N279D and R456W) simultaneously into two
heterologous viruses (Q842 and RHPA) neutralized by wave 2 but
not by wave 1 (Figure 1A), and tested them against plasma from
the peak of wave 2 activity (122 weeks p.i.). The mutants were at
least 20 fold more resistant to neutralization at this time point than
the wild-type viruses, confirming the role of CD4bs mutations in
escape from wave 2 antibodies (Figure 5A).
To further characterize the epitope targeted by wave 2
antibodies, we assessed the dependence of wave 2 binding on
the D368 residue in a3 (critical for VRC01-like antibodies), and
residues 474/475/476 in a5 (critical for HJ16-like antibodies)
by adsorption studies. The D368R or D474A/M475A/R476A
mutations were separately introduced into ConC gp120, and
compared to the wild-type protein for their ability to adsorb out
the neutralizing activity against Q842 and RHPA at peak wave
2 titers. Both mutant gp120s (Figure 5B – yellow and brown
bars) adsorbed out a significant fraction of the neutralizing
activity against Q842 and RHPA, equivalent to that adsorbed
by wild-type gp120 (Figure 5B – white bars). These data
suggested that CAP257 antibody binding was not dependent on
these residues in the a3 and a5 helices. CAP257 neutralization
could not be adsorbed with the RSC3 protein used to isolate
VRC01, which binds weakly to the HJ16 class of CD4bs
antibodies [55].
CAP257 wave 2 antibodies recognize a glycan dependent
epitope in the CD4bs, also recognized by the monoclonal
antibody HJ16
Of the three changes identified above as mediating escape from
wave 2 antibodies, N279 and R456 make contact with CD4, while
T278 forms part of an adjacent glycosylation sequon [6]. This
glycosylation sequon is conserved in 96% (n = 3,475) of envelope
sequences in the LANL HIV sequence database. Its deletion via
N276D/S or T278A/K mutations in later viruses (Figure 4) for
wave 2 escape was therefore striking, and suggested a possible role
for glycan recognition by CAP257 wave 2 antibodies. To examine
wave 2 glycan binding, we expressed an RHPA core gp120 in
GnTI(2/2) 293S cells, which allowed for deglycosylation of the
protein using Endo-H, and assessed the ability of both glycosylated
and deglycosylated proteins to adsorb out wave 2 neutralization
activity. While neutralizing activity against RHPA was efficiently
adsorbed with the glycosylated RHPA gp120 core (Figure 5C –
white bars), the deglycosylated protein only adsorbed out a
fraction of that activity (Figure 5C – purple bars) confirming the
importance of glycans in wave 2 antibody binding. Similarly HJ16
was not adsorbed by the deglycosylated protein suggesting glycan
dependence. In contrast, VRC01 was adsorbed equally effectively
by both proteins.
To assess in more detail the role of the N276 glycan in wave 2
neutralization, we generated four mutants in RHPA, comparing
the effects of two conservative mutations (N276Q, T278S) with the
effects of two alanine substitutions (N276A, T278A) in the N276
glycosylation sequon (Figure 5D – boxed in purple). Both alanine
mutations significantly affected wave 2 peak titers by 18 and 30
fold respectively. The N276Q mutation which deleted the glycan
but retained the amino acid properties at position 276 also affected
wave 2 neutralization by 21 fold (a similar effect to the N276A
mutation), while the T278S mutation that retained the N276
glycan had no effect on neutralization. These data suggested that
sensitivity to wave 2 neutralization was largely dependent on the
glycan at position 276, rather than the N276 amino acid side
chain. We also assessed the effect of the remaining two autologous
mutations in the CD4bs (N279D and R456W) identified above
(Figure 5D). The N279D mutation alone had a relatively small 2
fold effect on neutralization, suggesting only a minor role in escape
from wave 2. When an alanine was substituted at position 279
instead, wave 2 neutralization was enhanced. The R456W
mutation had a more significant 10 fold effect on CAP257
neutralization, but was still less effective than the glycan deleting
mutations at positions 276/278 which were the major escape
mutations.
We next compared the epitope for CAP257 wave 2 neutralizing
antibodies with that of HJ16 (CD4bs/DMR) and VRC01
(CD4bs). Both monoclonal antibodies were profoundly affected
by the R456W mutation (514 and 30 fold respectively). Like
CAP257, HJ16 neutralization was significantly dependent on the
glycan at position 276 with glycan deleting mutations (N276Q/A
and T278A) resulting in a 74–106 fold increase in IC50 (Figure 5D).
This dependence on the N276 glycan distinguished both CAP257
and HJ16 from VRC01, for which neutralization was slightly
enhanced (2–3 fold) when the glycan was removed. This effect on
VRC01 is consistent with previous studies showing that deleting
the N276 glycan exposes the CD4 binding site to neutralization by
VRC01 or b12 [52,56]. Introducing all three CAP257 escape
mutations identified above therefore had a compensatory effect on
VRC01 resistance (8 fold compared to 30 fold effect for R456W
alone), but completely abrogated HJ16 neutralization, confirming
the similarities between HJ16 and CAP257 plasma. Despite these
overall similarities, some differences were apparent between
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CAP257 wave 2 antibodies and HJ16, such as the preference of
HJ16 for the threonine at position 278 and the asparagine at
position 279. Unlike CAP257, the N279A mutation did not
enhance HJ16 neutralization but rather resulted in a 4 fold
reduction in titer. These data may suggest minor contacts between
HJ16 and the amino acid side chain at position 279.The N279A
mutation also significantly affected VRC01 neutralization (76
fold), consistent with either asparagine or aspartic acid residues at
position 279 being directly contacted by W100B in the CDR3-H3
of VRC01 [52,57].
To clarify the role of glycan binding we tested three CD4bs
neutralizing antibodies (VRC01, b12, and HJ16) in ELISA for
binding to either the glycosylated or deglycosylated RHPA gp120
core proteins (Figure 5E). The neutralizing antibody 2G12 has a
well-defined glycan epitope and was used as a positive control [58–
62], while CAP88-3468L (a V3 binding antibody) served as a
negative control [63]. Deglycosylation significantly affected the
binding of both 2G12 and HJ16 (Figure 5E – blue and purple
curves), but did not significantly affect binding of either VRC01 or
b12 (Figure 5E – green and yellow curves) to the RHPA gp120
core. These data confirmed the glycan binding properties of HJ16,
and suggest that both CAP257 wave 2 neutralizing antibodies and
HJ16 have a glycan dependent mechanism of neutralization at the
CD4bs.
Early wave 2 escape mutations drive an increase in
neutralization breadth
While the simultaneous introduction of T278A, N279D, and
R456W mutations into heterologous viruses Q842 and RHPA
made them resistant to wave 2 neutralization at 122 weeks p.i.
(Figure 5A), when each mutation was introduced individually into
RHPA the results were varied (2–30 fold reductions in titer) with
no single mutation resulting in complete escape (Figure 5D).
These data suggested that escape from wave 2 required a
combination of all three mutations. Longitudinal sequence
analysis showed that the N279D mutation emerged first at 93
weeks in 5% of the population, followed by N276D/S glycan
deleting mutations at 122 weeks in 36% of the population, and
then by substitution of the R456 residue with a bulky amino acid
side chain (H, Y, or W) at 161 weeks p.i. in 17% of the
population (Figure 4).
Figure 4. Accumulating escape mutations from wave 2 broadly neutralizing antibodies occur in the CD4 binding site. Amino acid
sequence alignment of the CAP257 D loop and b23 regions of gp120 from seven time points. The number of envelopes per unique sequence is
shown on the right. The timing of wave 1 (red), wave 2 (green), and wave 3 (brown) neutralization is summarized to the left with vertical lines. Amino
acids contacting CD4 (as described in [57]) are indicated above the sequence alignment, with # denoting backbone only contacts, denoting side
chain contacts, andN denoting main chain and side chain contacts. Potential N-linked glycans are shaded grey. The frequency of escape mutations at
position 279 (orange slices), in the N276/T278 glycosylation sequon (purple slices), or at position 456 (pink slices) for each time point is shown with
pie charts.
doi:10.1371/journal.ppat.1003738.g004
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To better characterize their contributions to escape from wave 2
antibodies, each mutation (T278A, N279D, and R456W) was
introduced separately into Q842 and RHPA and compared to the
wild-type viruses. The N279D mutation (Figure 6 – orange curves)
had a significant effect only at the beginning of wave 2 activity
against Q842, shifting the earliest heterologous neutralization of
Q842 from 80 weeks to 93 weeks p.i. (with a 5 fold effect on titers
at 107 weeks p.i.). The mutation also affected the titers against
RHPA by 2–3 fold. This suggested an initial dependence on N279,
with later wave 2 antibodies being less vulnerable to mutations at
this residue. This reduced dependence on N279 coincided with the
emergence of the N279D mutation at 93 weeks p.i. (Figure 6 –
orange dotted lines) providing a mechanism for maturation of the
antibody response. The T278A mutation (Figure 6 – purple
curves) that deleted the N276 glycan conferred almost complete
resistance in Q842, and shifted the earliest neutralization of
RHPA from 67 to 122 weeks p.i. The R456W mutation (Figure 6
– pink curves) did not result in a further right shift in the
neutralization curves for RHPA relative to the T278A mutation,
but did affect the neutralization kinetics of Q842 relative to the
wild-type or N279D mutant viruses. As with the N279D mutation,
these changes in the fine specificity of the maturing antibody
response reflected the emergence of either T278A or R456W
mutations in longitudinal autologous sequences (Figure 6 – purple
and pink dotted lines respectively).
These data are consistent with accumulating resistance to wave
2, and suggest that after each successive round of escape, new
antibody variants emerged that were able to neutralize first the
N279D mutant, and then later autologous viruses with additional
polymorphisms at positions 276, 278, or 456. We wished to
determine whether the ability to neutralize escaped viral variants
correlated with increased wave 2 neutralization breadth. Heter-
ologous viruses neutralized by wave 2 were divided into two
groups, those neutralized at 67 weeks p.i. (early wave 2
neutralization), and those first neutralized at 93 weeks p.i. (late
wave 2 neutralization) after the emergence of initial wave 2 escape
mutations (Figure 7A). Viruses also neutralized by wave 1 were
omitted as the overlapping titers confounded this analysis.
Inspection of the envelope sequences (particularly in the D-loop)
showed that all of the viruses neutralized by early wave 2
antibodies had the N279 immunotype (Figure 7B – boxed in
orange). In contrast 44% of viruses neutralized by later wave 2
antibodies had the D279 immunotype. Furthermore, of the viruses
neutralized by later wave 2 antibodies, one (Q259) lacked the
N276 glycan and four others also had additional non-conservative
mutations at positions 273–275 in the N-terminus of the D-loop
Figure 5. CAP257 broadly neutralizing antibodies bind a glycan dependent epitope in the CD4bs, also targeted by mAb HJ16. A)
Effect of escape mutations T278A, N279D, and R456W in the CD4bs on wave 2 neutralization. ID50 titers at 122 weeks p.i. (y-axis) are shown for Q842
and RHPA (black bars), or the corresponding triple mutants (red bars). B) Adsorption of peak wave 2 titers (122 weeks p.i.) with wild-type or mutant
gp120 proteins. The residual neutralizing activity in the adsorbed plasma samples is shown as ID50 titers (y-axis) for the heterologous viruses Q842
and RHPA. Untreated plasma is shown in black, plasma adsorbed with blank beads in grey, plasma adsorbed with ConC gp120 in white, plasma
adsorbed with D368R mutant gp120 in yellow, plasma adsorbed with D474A/M475A/R476A triple mutant gp120 in brown, and plasma adsorbed with
RSC3 protein in orange. C) Effect of glycosylation on the CAP257 wave 2 epitope in RHPA. The fold reduction in titer (y-axis) of adsorbed samples
from 122 weeks p.i. are shown for CAP257 wave 2, HJ16, and VRC01. Plasma adsorbed with blank beads is shown in grey, gp120 core in white, and
deglycosylated gp120 core in purple. D) The dependence of CAP257 wave 2 neutralizing antibodies (at 122 weeks p.i.) on D-loop and b23 residues/
glycans in RHPA, compared to the monoclonal antibodies HJ16, VRC01, and 10E8. The effect of N276 glycan mutations on CAP257 plasma is boxed in
purple, and the presence or absence of a glycan at N276 for each mutation is indicated. Fold effects between 2–10 are yellow, 10–100 colored orange,
and .100 colored red. Triple* is the triple mutant described in A. E) Effect of glycosylation on the HJ16 epitope. The ELISA OD at 450 nm is shown (y-
axis) versus antibody concentration (x-axis). Binding to glycosylated or deglycosylated gp120 core is shown with solid or open circles respectively.
The monoclonal antibodies tested were VRC01 (green), b12 (yellow), HJ16 (purple), 2G12 (blue), and CAP88-3468L (grey).
doi:10.1371/journal.ppat.1003738.g005
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(Figure 7B – boxed in blue) that may also affect early wave 2
neutralization. These data suggest that wave 2 escape mutations
guided maturation of the CD4bs response, enabling later wave 2
antibodies to neutralize additional heterologous viruses and
ultimately resulting in the increased neutralization breadth of
CAP257 plasma.
The wave 3 neutralizing antibody target is distinct but
undefined
Like wave 1, wave 3 neutralization could not be adsorbed with
monomeric gp120, suggesting that these antibodies targeted a
quaternary epitope, or an epitope in gp41. To assess whether wave
3 was a distinct antibody specificity, or a re-emergence of wave 1
antibodies, we selected a virus (Du156) that was sensitive to waves
1 and 3, and less sensitive to wave 2 (Figure 8A – red curve).
Resistance to wave 1 (V2) and wave 2 (CD4bs) neutralizing
antibodies was established by introducing the N160K and T278A
mutations identified above. The resulting virus (Du156 N160K/
T278A) remained sensitive to wave 3 neutralization only
(Figure 8A – brown curve), suggesting that wave 3 differed from
wave 1 (which was completely abrogated by the N160K mutation).
To confirm this, we introduced additional V2 mutations (R166A,
K168A, K169E, K171A) known to abolish wave 1 neutralization,
into the Du156 double mutant. None of these mutations
significantly affected the titers of wave 3 neutralizing antibodies
(Figure 8A – yellow curves), confirming that the epitope for wave 3
antibodies did not overlap with the wave 1 V2 epitope. An N332A
mutation was also introduced to confirm that wave 3 antibodies
did not target this glycan.
To test whether CAP257 wave 3 neutralizing antibodies
targeted the MPER region of gp41, we coupled MPER peptides
to magnetic beads and used them to adsorb out MPER specific
binding antibodies in CAP257 plasma. The adsorption of MPER
binding antibodies (Figure 8B) did not affect neutralization of
Du156 or the double mutant Du156 N160K/T278A (with wave 1
and 2 resistance mutations) when compared to untreated plasma
(Figure 8C). Thus, while we cannot exclude the possibility that
wave 3 antibodies target V2 or gp41, these neutralizing antibodies
appear to target an epitope distinct from any of the four known
sites of vulnerability in the HIV-1 envelope.
CAP257 viruses develop resistance to known broadly
neutralizing antibodies
We hypothesized that the selection pressure exerted by these
broadly neutralizing antibodies would impact on the overall
neutralization phenotype of CAP257 viruses over time. Therefore
we tested the sensitivity of envelopes from 7, 30, 54, 93, and 174
weeks p.i. to broadly neutralizing monoclonal antibodies targeting
the four major epitopes (Figure 9). The 7 week clone from
CAP257 was sensitive to neutralization by anti-V2 antibodies, but
following the development of wave 1 V2 neutralizing antibodies,
CAP257 viruses became more resistant to PG9 and PGT145
neutralization. The 7 week clone was also highly sensitive to HJ16
(0.02 mg/mL) and VRC01 (1.79 mg/mL), however clones isolated
after the emergence of wave 2 neutralization were increasingly
resistant to neutralization by antibodies targeting the CD4bs.
CAP257 viruses from all the time points selected were sensitive to
neutralization by antibodies targeting the MPER or N301/N332,
neither of which was targeted by broadly neutralizing antibodies in
CAP257 plasma. These data confirm that CAP257 developed
broadly neutralizing antibodies targeting the CD4bs and V2.
Furthermore, the finding that CAP257 viruses remained sensitive
to neutralization by antibodies targeting N301/N332 and the
MPER supports our hypothesis that wave 3 antibodies target a
novel epitope on the HIV-1 envelope.
Discussion
A preventative HIV-1 vaccine remains the most likely way to
end the HIV pandemic, but current envelope immunogens have
so far failed to elicit broadly neutralizing antibodies. Nonetheless,
the development of cross-reactive antibodies in approximately a
quarter of HIV-1 infected individuals has confirmed that the
human immune system can make such antibodies. Much emphasis
has been placed on mapping the targets for these broadly
neutralizing antibodies in an attempt to define viral vulnerabilities
for immunogen design. Here we analyzed CAP257 heterologous
neutralization over a 4.5 year period, describing the sequential
evolution of three distinct broadly neutralizing antibody specific-
ities within a single HIV-1 subtype C infected individual. We
further showed how early viral evolution in the context of broadly
reactive antibodies may profoundly shape the maturing antibody
Figure 6. Changes in the fine specificity of CAP257 CD4bs antibodies in response to autologous escape mutations. The longitudinal
neutralization of Q842 (green) or RHPA (blue) wild-type (wt) viruses was compared to the neutralization of N279D (orange), T278A (purple), and
R456W (pink) mutant viruses. The triple mutant (T278A/N279D/R456W) from Figure 5A is also shown in red. ID50 titers (y-axis) are shown versus weeks
p.i. (x-axis). Dotted lines indicate the time points at which each mutation (D = N279D, A = T278A, W = R456W) first appears in the autologous
sequences (colored as above).
doi:10.1371/journal.ppat.1003738.g006
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response towards enhanced neutralization breadth, in a process
that may inform immunogen design. These data have been
summarized in Figure 10.
The CAP257 autologous virus efficiently escaped all three
specificities. As a consequence the antigenic stimulus for these
broadly neutralizing antibodies declined, and antibody titers
dropped at least ten fold within a three year period. The waxing
and waning of the broadly neutralizing specificities in CAP257
confounded our previous attempts to map the targets at 174 weeks
p.i. [7], when the titers of the three waves overlapped significantly.
As most mapping studies are cross-sectional, the number of
individuals who mount multiple broadly neutralizing antibody
responses may therefore be underestimated, and may make up a
significant proportion of those plasma samples that remain
undefined.
Nonetheless we were able to finely map 2 of the 3 specificities in
this study and showed that they targeted known sites of
vulnerability on the HIV-1 envelope. Wave 1 antibodies targeted
the site defined by PG9/16 and were completely dependent on
N160 and K169, consistent with previous data describing PG9/16
dependence on the N160 glycan and the positively charged amino
acids in the C-strand of V1/V2 [16,37]. In general the epitope for
wave 1 antibodies showed a larger footprint in V2 when compared
to the epitopes of other monoclonal antibodies targeting this site,
but behaved most similarly to PGT145. However none of the
antibodies or plasma tested was sensitive to removal of the N156
glycan. While the crystal structure of PG9 with V2 showed
interactions with the N156 glycan [37], the effect of deleting the
N156 glycan is variable [16,35,36]. This effect might be explained
by recent data suggesting that PG9 recognizes two N160 glycans
(from two adjacent gp120 monomers) but only one N156 glycan
[64]. The requirement for a lysine at position 169 explains the
subtype C specificity of CAP257 wave 1 antibodies, as this residue
is less common in subtypes A and B [35].
Wave 2 antibodies targeted a known site of vulnerability, the
CD4bs, but these antibodies had an unusual glycan dependent
mechanism of neutralization. CAP257 wave 2 and HJ16
neutralization were both highly dependent on interactions with
the N276 glycan. N276 is also the recently described target of the
broadly neutralizing antibody 8ANC195, but this antibody does
not appear to interact with the CD4bs [65]. While glycan
dependence for neutralization has not previously been described
for CD4bs antibodies, including HJ16, Balla-Jhagjhoorsingh et al.
reported that resistance to HJ16 involved an N276D mutation
(deleting the glycan) with a hundred fold drop in titer [66],
providing support for our observations. The glycan dependence of
both HJ16 and CAP257 wave 2 antibodies suggests that they
target a similar sub-epitope of the CD4bs that may be better
defined as an N276 glycan dependent class of neutralizing
antibodies, which is distinct from the VRC01 class. Recently it
was shown that related variants of VRC01 do bind the glycan at
N276 [67], however this glycan is not a major determinant of
neutralization sensitivity to VRC01 [52,56,57,68]. Rather, N276
has been described as a protective shield for the CD4bs, and
deleting this glycan enhances the neutralization of CD4bs
antibodies VRC01 and b12 [52,56]. Removing N276 from
gp120 also enabled binding to the predicted germline antibody
for VRC01, which otherwise did not bind to gp120, and has been
suggested as a modification for candidate vaccine immunogens
[69,70]. However, the glycan shield is increasingly recognized as a
major site of vulnerability on the HIV-1 envelope [15,16], and as
with the glycans at N156/N160 and N301/N332, conservation of
the N276 glycan bordering the CD4bs may make it a promising
target for vaccine design.
Figure 7. Maturation of the wave 2 CD4bs response results in
the increased neutralization breadth of CAP257 plasma. A)
Summary of early (green) and late (blue) heterologous neutralization by
wave 2 antibodies superimposed over the individual virus neutralization
kinetics (grey). Viruses neutralized by V2 antibodies in wave 1 have
been excluded. ID50 titers (y-axis) are shown versus weeks p.i. (x-axis). B)
Amino acid sequence alignment of heterologous viruses depicted in (A).
The timing of early or late heterologous neutralization is shown on the
left with horizontal lines. The N276 glycan is shaded grey, and position
279 is boxed in orange. The frequency of the N279D mutation or
disrupted N276 glycosylation within the two groups is shown with
orange or purple pie slices respectively. The N-terminal region of the D-
loop is boxed in blue.
doi:10.1371/journal.ppat.1003738.g007
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Characterization of viral escape from CAP257 CD4bs antibod-
ies indicated that deletion of the N276 glycan alone did not confer
complete resistance. Escape required accumulating mutations in
the CD4bs site, consistent with the functional conservation of this
epitope. In addition to deletion of the N276 glycan, CAP257
escape occurred through a R456W mutation that also significantly
affected neutralization by VRC01 (30 fold) and HJ16 (514 fold).
This mutation likely contributed towards the evolution of VRC01
resistant virus by 174 weeks. W456 is extremely rare, occurring in
only 0.78% (27 of 3,481) of sequences in the LANL HIV-1
sequence database. A crystal complex for HJ16 is not available,
however the structure of VRC01 bound to its epitope showed that
this antibody does not make significant contact with the R456 side
chain in gp120, but rather hydrogen bonds with the R456
backbone carbonyl group. This suggests that the R456W mutation
provides an indirect mechanism for resistance. The highly
conserved R456 side chain can make hydrogen bonds with
backbone carbonyl groups of amino acids at position 277 and 278
in the D-loop, as well as hydrogen bonds with E466 side chain in
b24, C-terminal to V5 (Figure 11). Loss of these bonds and
Figure 8. Wave 3 neutralizing antibodies target a novel epitope. A) Neutralization of Du156 wild-type (wt) virus by longitudinal CAP257
serum is shown in red. The timing of wave 1 (red), wave 2 (green), and wave 3 (brown) neutralization is summarized above as horizontal lines, with
peak titers of each wave indicated with dotted lines. The Du156 N160K/T278A double mutant is shown in brown. Du156 triple mutants N160K/
T278A/(R166A, K168A, K169E, K171A, or N332A) are shown in yellow. ID50 titers (y-axis) are shown versus weeks p.i. (x-axis). B) Adsorption of MPER
binding antibodies. OD (450 nm) against the MPER peptide is shown (y-axis) versus plasma dilution (x-axis). Untreated plasma is shown in black, and
MPER adsorbed plasma in brown. C) Adsorption of wave 3 neutralization by MPER (colored as above). ID50 neutralization titers at 213 weeks p.i. (y-
axis) are shown for Du156 and Du156 N160K/T278A.
doi:10.1371/journal.ppat.1003738.g008
Figure 9. Accumulating resistance of CAP257 clones to broadly neutralizing monoclonal antibodies targeting V2 and the CD4bs.
The sensitivity of nine CAP257 clones from 7, 30, 54, 93, and 174 weeks p.i. to broadly neutralizing antibodies targeting the four known sites of
vulnerability was measured in a TZM-bl assay. The timing of wave 1 (red), wave 2 (green), and wave 3 (brown) neutralization is summarized above
with arrows. Increases in IC50 relative to the 7 week clone are colored as follows: 5–10 fold (yellow), .10 fold (orange), complete neutralization
resistance (red).
doi:10.1371/journal.ppat.1003738.g009
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Figure 10. Summary of the role of CAP257 viral evolution in shaping broadly neutralizing antibody responses. The schema depicts
the evolution of plasma neutralizing antibodies and viral escape mutations over 240 weeks. Each of the three waves of CAP257 broadly neutralizing
antibodies is shown. Text boxes highlight the key events described herein. Env trimers (EMD-5447) were drawn in UCSF-Chimera, and spheres were
used to approximate the location of escape mutations. 1) Strain-specific antibodies (dotted orange line) developed at 23 weeks, targeting a V2
epitope overlapping with known V2 antibodies (eg: PG9). 2) Strain-specific V2 antibodies were escaped by an N167D mutation (D being the global
consensus at this site). 3) Broadly neutralizing antibodies targeting V2 (wave 1 – red curve) developed at 30 weeks. 4) Escape from wave 1 antibodies
through deletion of the N160 glycan was associated with exposure of an epitope in the CD4bs. 5) At 67 weeks broadly neutralizing antibodies
targeting the CD4bs (wave 2 – green curve) develop. Neutralization was N276 glycan dependent and sensitive to an N279D mutation. 6) The N279D
change emerges at 93 weeks, significantly affecting wave 2 neutralization at this time point. 7) Wave 2 neutralization becomes independent of
position 279, which was associated with increased neutralization breadth. 8) Mutations that delete the N276 glycan (as well as an R456W change)
escape wave 2 antibodies. 9) CAP257 develops a third broadly neutralizing antibody specificity that could not be mapped to any of the four known
antibody targets.
doi:10.1371/journal.ppat.1003738.g010
Figure 11. The R456 side chain stabilizes the CD4bs epitope through hydrogen bonding. A diagram of the 93TH057 gp120 crystal
structure (pdb file 4JKP) shown in an orientation similar to the angle of approach for CD4. The crystalized part of the N276 attached glycan
(GlcNAc2Man4) is shown with purple spheres. The D-loop is shown in green, the V5 loop is shown in cyan, and the R456 residue is shown in pink.
Oxygen atoms are colored red, and nitrogen atoms blue. The inset shows a magnified view of the interaction between R456 and residues in the D-
loop or the b24 strand. Putative hydrogen bonds are shown with dotted orange lines. The image was created using The PyMOL Molecular Graphics
System, Version 1.3r1edu, Schrödinger LLC.
doi:10.1371/journal.ppat.1003738.g011
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localized conformational changes to accommodate a bulky
tryptophan residue may destabilize this critical component of the
CD4bs epitope [52,56,71].
This study adds to data showing that the immune system can
target multiple conserved epitopes [29–31]. It is striking that in
three of these four studies, antibodies targeted both V2 and the
CD4bs (donors CH219, AC053, and CAP257), suggesting an
association between these two epitopes. Indeed, there is a well-
documented relationship between V1/V2 and the CD4bs. The
V1/V2 region protects the receptor binding sites from neutrali-
zation [42–51], and also interacts with V3 at the trimerization
domain to hold the CD4bs in its pre-liganded conformation [21].
The crystal structures of monoclonal antibodies PG9, CH58, and
CH59 bound to their epitopes in V2 show that the conformation
of the V1/V2 sub-domain may vary significantly, but the factors
that govern these conformational states are not known [37,72]. In
CAP257, deletion of the N160 glycan increased exposure of the
CD4bs. It is possible that certain immunotypes of the V1/V2
epitope, such as the rare mutations at N160 or D167 described
here, shifted the equilibrium of V1/V2 toward conformations that
better exposed the CD4bs to neutralizing antibodies. This is
supported by previous observations that introduction of the
N160K and D167N mutations simultaneously into JR-FL resulted
in a .50 fold increase in neutralization sensitivity to CD4bs
antibodies [73]. CAP257 was infected with the less common N167
variant, and therefore following escape from V2 wave 1 antibodies
a similar conformational state (D/S160, N167) would have been
presented to the immune system. Our data suggest that this escape
pattern further exposed the glycan dependent CD4bs sub-epitope.
Although vaccination with the K160 and/or N167 immunotype
may improve antibody responses to the CD4bs site, antibodies
induced to the V2 epitope would be relatively strain-specific, like
monoclonal antibody 2909 that recognizes the K160 immunotype
and is therefore specific for SF162 [74]. In CAP257, switching
from N167 to the more common D167 residue resulted in escape
from the strain-specific response to V2, and this coincided with the
development of a much broader response targeting the same
epitope.
Sequential immunization may be a useful strategy to promote
the broadening of the B-cell response. Recently Murphy et al.
showed that two light chain variants paired with a single heavy
chain of a strain-specific neutralizing antibody differentially
neutralized early autologous envelopes [75]. While evolution of
that strain-specific epitope did not affect the development of
broadly neutralizing antibodies in this individual, the data supports
the possibility that viral evolution might facilitate the neutraliza-
tion of amino acid variants within a given epitope. Similarly, we
have previously shown in an individual who developed broadly
neutralizing antibodies to the V2 region that viral escape drove a
maturation of the antibody response towards recognizing multiple
V2 variants [35]. Here we show that emergence of an aspartic acid
at position 279 preceded a broadening of the B-cell response to the
CD4bs. The N279 and D279 amino acid variants of the CD4bs
are equally common among sequences in the LANL HIV-1
database (50% and 48% respectively, n = 3,479), and preferential
neutralization of either immunotype would halve the neutraliza-
tion breadth of an antibody. CAP257 wave 2 neutralizing
antibodies and HJ16 were somewhat sensitive to the N279D
change. However the resistance of D279 containing viruses to
CAP257 antibodies was rapidly lost after the emergence of the
N279D escape mutation. Therefore, like the N167D mutation in
V2 described for wave 1, this change in the fine specificity of
CAP257 antibodies coincided with an increase in the neutraliza-
tion breadth of the CD4bs response. We hypothesize that position
N279 was non-critical for antibody binding, and despite tempo-
rarily facilitating neutralization escape, the N279D mutation then
promoted affinity maturation by reducing the dependence of
CAP257 antibodies on this amino acid. This adds to recent data
suggesting a major role for viral evolution in the development of
neutralization breadth to the CD4bs [76]. These data support the
possibility that a sequential immunization strategy would enhance
neutralization breadth by systematically presenting common
variants in a given epitope. Such residues would have to be non-
critical to antibody binding allowing for the evolution of higher
affinity variants that would in turn recognize multiple immuno-
types.
Overall these data highlight how interactions between the host
immune system and viral escape mutations shaped the develop-
ment of broadly neutralizing antibodies. The escape pathways
identified here that led to the increased breadth of neutralization
for both V2 and CD4bs antibodies provide potential pathways for
generating broadly neutralizing antibodies. Further defining these
pathways through the isolation of monoclonal antibodies will
provide valuable insight into how these types of antibodies could
be elicited using sequential immunization in a vaccine setting.
Materials and Methods
Ethics statement
The CAPRISA Acute Infection study received ethical approval
from the Universities of KwaZulu-Natal (E013/04), Cape Town
(025/2004), and the Witwatersrand (MM040202). CAP257
provided written informed consent for study participation.
CAPRISA 002 Acute Infection cohort participant
The CAPRISA Acute Infection cohort is comprised of women
at high risk of HIV-1 infection in Kwa-Zulu Natal, South Africa
[77]. Here we studied one individual (CAP257) from seven weeks
p.i. through four and a half years of infection, until she started
anti-retroviral therapy. During this time she had an average viral
load of 60,784 copies/mL and an average CD4 count of 498 cells/
mL. Plasma samples collected at 30 time points were used in this
study.
Single genome amplification
The amplification of envelope genes from single HIV-1 RNA
genomes has been previously described [78]. Viral RNA was
isolated from CAP257 plasma using a Viral RNA Extraction Kit
(QIAGEN), and cDNA was synthesized with Superscript III
Reverse Transcriptase (Invitrogen). The reaction product was
treated with RNase H (Invitrogen) and envelope genes were
amplified by nested PCR with Platinum Taq (Invitrogen).
Amplicons were purified with a PCR Clean-up Kit (QIAGEN)
and single genome amplification confirmed by DNA sequencing
using the ABI PRISM Big Dye Terminator Cycle Sequencing
Ready Reaction kit (Applied Biosystems) and an ABI 3100
automated genetic analyzer. The full-length env sequences were
assembled and edited using Sequencher v.4.5 (Genecodes) and
Bioedit v.7.0.5.3.
Cell lines
The TZM-bl cell line engineered from CXCR4-positive HeLa
cells to express CD4, CCR5, and a firefly luciferase reporter gene
(under control of the HIV-1 LTR) was obtained from the NIH
AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH (developed by Dr. John C. Kappes, and Dr.
Xiaoyun Wu [79,80]). The 293T cell line was obtained from Dr
George Shaw (University of Alabama, Birmingham, AL). Cells
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were cultured at 37uC, 5% CO2 in DMEM containing 10% heat-
inactivated fetal bovine serum (Gibco BRL Life Technologies)
with 50 ug/ml gentamicin (Sigma) and disrupted at confluency by
treatment with 0.25% trypsin in 1 mM EDTA (Sigma).
Pseudovirus production
Selected envelope sequences were re-amplified from first round
nested PCR products (described above) with PfuUltra II
(Stratagene), purified by a Gel Extraction Kit (QIAGEN) and
cloned into pcDNA3.1 (Invitrogen). The envelope plasmids were
co-transfected into 293T cells using FuGENE 6 (Roche) with the
pSG3DEnv backbone (obtained from the NIH AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID,
NIH). Cultures were incubated for 48 hours to produce Env-
pseudotyped viral stocks that were filtered through 0.45 mm and
frozen in DMEM supplemented with 20% FBS. Mutant envelopes
were generated with the QuikChange Lightning Kit (Stratagene)
and confirmed by DNA sequencing (as above).
Neutralization assay
The TZM-bl neutralization assay has been described previously
[4,81]. It measures a reduction in relative light units generated by
a single round of infection in TZM-bl cells with Env-pseudotyped
viruses after pre-incubation with monoclonal antibodies or a
plasma sample of interest. Samples were serially diluted 1:3 and
the ID50 calculated as the dilution at which the infection was
reduced by 50%.
Protein expression and adsorptions
Plasmids encoding Histidine tagged recombinant envelope
proteins were transfected into 293T cells using polyethylenimine
25 kDa (Polysciences). Recombinant proteins were expressed and
purified as previously described [9]. Aliquots of 400 mg each were
coupled to MyOne Tosyl-activated magnetic Dynabeads (Invitro-
gen) at 37uC pH 9.5 overnight, and then blocked with 0.5% BSA
in 0.05% Tween20 PBS overnight at 37uC. Protein coupled beads
were incubated with 200 mL of plasma (diluted 1:20) for two hours
at 37uC, then the beads were removed magnetically and the
remaining plasma assessed for binding and neutralizing antibodies
using ELISA and neutralization assays respectively.
Enzyme Linked Immunosorbent Assay (ELISA)
Protein antigens were coated at 4 mg/mL onto high binding 96-
well ELISA plates (Corning) overnight at 4uC. All subsequent steps
were carried out in 5% fat-free milk, 0.05% Tween20 in PBS for
1 hour at 37uC. The plates were blocked and then probed with
serial dilutions of the adsorbed plasma or specific monoclonal
antibodies, biotinylated goat anti-human polyclonal antibodies
(KPL), and an anti-biotin monoclonal conjugated to HRP
(Calbiochem). Antigen-antibody complexes were detected by
incubating with 100 mL 1-Step Ultra TMB-ELISA (Thermo-
scientific) for five minutes and then the reaction was stopped with
25 mL 1 M H2SO4. Absorbance was read at 450 nm on a
VERSAmax tunable microplate reader (Molecular devices).
Protein deglycosylation
Plasmid encoding the RHPA gp120 core was transfected with
polyethylenimine-MAX 40 kDa (Polysciences) into GnTI(2/2)
293S cells and purified using two step lectin chromatography and
Ni-NTA affinity chromatography. Protein was assessed for purity
and conformation by SDS-PAGE and ELISA. 1 mg of the RHPA
core gp120 was deglycosylated overnight at 37uC in 500 mM
sodium chloride, 100 mM sodium acetate pH 5.5 with 0.5 U of
Endo-H. Glycans were removed through buffer exchange into
PBS using Vivaspin 20 mL concentrators (Sartorius stedim).
Deglycosylation was confirmed by SDS-PAGE and sandwich
ELISA (described above) using lectins as a capture protein.
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